At Last, AZ’s Imfinzi/Tremelimumab Cancer Combo Shows Survival Benefit

Could Signal First Tremelimumab Approval

 
• By Andrew McConaghie
AstraZeneca
While Tagrisso is a market leader in targeted NSCLC treatment, AZ's immuno-oncology franchise lags behind other competitors.

More from Business

More from Scrip